Know Cancer

or
forgot password

A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)


OBJECTIVES:

- Determine whether the 64-gene signature can accurately predict the prognosis for
survival of patients with stage I non-small cell lung cancer (NSCLC).

OUTLINE: RNA is purified from tissue samples obtained by the CALGB Lung Cancer Study
(CALGB-140202). The RNA samples are used for gene expression analysis using the 64-gene
signature and an Affymetrix-HG_U133A array. Reverse-transcriptase PCR may also be performed
on selected samples.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of stage I non-small cell lung cancer

- Enrolled in tissue repository CALGB 140202

PATIENT CHARACTERISTICS:

- Caucasian race

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Overall survival, defined as the time from surgery to death of any cause

Safety Issue:

No

Principal Investigator

Ming You, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Washington University Siteman Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000649826

NCT ID:

NCT00990873

Start Date:

July 2009

Completion Date:

Related Keywords:

  • Lung Cancer
  • stage I non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location